Back from the ECTRIMS 2025 conference in Barcelona, Dr Jiwon Oh reports on several promising results from relapsing-remitting multiple sclerosis (RRMS) clinical trials. A UK phase 2 study showed that combined clemastine and metformin stabilized visual evoked potentials in relapsing MS patients, suggesting potential remyelination benefits.
The FENopta trial revealed that fenebrutinib, a BTK inhibitor, nearly suppressed all disease activity over 2 years, showing greater efficacy than some other BTK inhibitors. Additionally, long-term extension data from the frexalimab trial demonstrated sustained low disease activity and good safety over 2.5 years, with upcoming phase 3 results anticipated.
